Corona Remedies has announced a Rs. 400 million expansion of its Bhayala manufacturing facility to enhance production capacity. 

The investment is aimed at meeting growing demand across key therapeutic segments in domestic and export markets. 

The expansion will also support backward integration and operational efficiency. 

This move reflects continued capital investment by Indian pharma companies amid sustained healthcare demand.

Company : Corona Remedies

---

Recent News

◉ Montecarlo declared L1 for Hadapsar–Yevat highway upgrade in Maharashtra - Feb 02,2026
◉ Corona remedies to expand Bhayala facility at a cost of Rs. 400 million - Jan 31,2026
◉ Green panel clears Dulhasti Hydel project on Chenab - Jan 31,2026
◉ Ahasolar Technologies wins 875 MW Solar O&M contract - Jan 31,2026
◉ IFFCO inaugurates Nano fertiliser facility in Bengaluru - Jan 31,2026
◉ Mahindra Susten commissions 560 MWp solar projects - Jan 31,2026
◉ Olectra Greentech commences commercial operations at greenfield EV manufacturing facility - Jan 31,2026